E-LIB Suche - Ergebnisse für: Seymour, J.F.

1

Outcome and feasibility of radiotherapy bridging in large B..:

Kuhnl, A. ; Roddie, C. ; Kirkwood, A. A....
British Journal of Haematology. 205 (2024) 2 - p. 483-494 , 2024

Link: https://doi.org/10.1111/..

2

Prognostic impact of HLA‐I neoantigen‐specific CD8+ T cells..:

Tobin, J. W. ; Tsang, H. ; Patch, A....
Hematological Oncology. 41 (2023) S2 - p. 276-277 , 2023

Link: https://doi.org/10.1002/..

3

Glofitamab plus R‐CHOP or polatuzumab vedotin‐R‐CHP is deli..:

Minson, A. ; Verner, E. ; Giri, P....
Hematological Oncology. 41 (2023) S2 - p. 421-422 , 2023

Link: https://doi.org/10.1002/..

4

RITUXIMAB‐CONTAINING COMBINED MODALITY THERAPY IN LIMITED S..:

Tobin, J. W. ; Jurinovic, V. ; Tsang, H....
Hematological Oncology. 41 (2023) S2 - p. 216-217 , 2023

Link: https://doi.org/10.1002/..

5

Improved outcomes of large B‐cell lymphoma patients treated..:

Boyle, S. ; Roddie, C. ; O'Reilly, M....
British Journal of Haematology. 204 (2023) 2 - p. 507-513 , 2023

Link: https://doi.org/10.1111/..

6

Ibrutinib (Ibr) for treatment of relapsed‐refractory (R/R) ..:

Ghia, P. ; Munir, T. ; Burger, J....
Hematological Oncology. 41 (2023) S2 - p. 464-466 , 2023

Link: https://doi.org/10.1002/..

7

Characterization of Mechanisms of Resistance in Previously ..:

Woyach, J. A. ; Jones, D. ; Jurczak, W....
Hematological Oncology. 41 (2023) S2 - p. 249-250 , 2023

Link: https://doi.org/10.1002/..

8

RADIOTHERAPY BRIDGING IN LARGE B‐CELL LYMPHOMA PATIENTS REC..:

Kuhnl, A. ; Roddie, C. ; Kirkwood, A....
Hematological Oncology. 41 (2023) S2 - p. 217-218 , 2023

Link: https://doi.org/10.1002/..

9

MURANO: Final 7 year follow up and retreatment analysis in ..:

Kater, A. P. ; Harrup, R. ; Kipps, T. J....
Hematological Oncology. 41 (2023) S2 - p. 239-242 , 2023

Link: https://doi.org/10.1002/..

10

S206: OBINUTUZUMAB PLUS CHEMOTHERAPY DEMONSTRATES LONG-TERM..:

Townsend, W. ; Hiddemann, W. ; Buske, C....
HemaSphere. 6 (2022) - p. 107-108 , 2022

Link: https://doi.org/10.1097/..

11

P670: ABSENCE OF BTK, BCL2, AND PLCG2 MUTATIONS IN RELAPSIN..:

Croner, L. J. ; Allan, J. N. ; Jain, N....
HemaSphere. 6 (2022) - p. 568-569 , 2022

Link: https://doi.org/10.1097/..

12

S146: VENETOCLAX IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKE..:

Stilgenbauer, S. ; Tausch, E. ; Roberts, A. W....
HemaSphere. 6 (2022) - p. 47-48 , 2022

Link: https://doi.org/10.1097/..

13

Central nervous system manifestations of systemic haematolo..:

Lasocki, A. ; Seymour, J.F.
Clinical Radiology. 77 (2022) 5 - p. 328-336 , 2022

Link: https://doi.org/10.1016/..

14

Prospective Phase II Trial of Radiation Therapy in Localize..:

MacManus, M.P. ; Roos, D.E. ; O'Brien, P....
International Journal of Radiation Oncology*Biology*Physics. 111 (2021) 3 - p. S105 , 2021

Link: https://doi.org/10.1016/..

15

UNFAVORABLE GENETICS IMPACT MRD RESPONSE TO VENETOCLAX+RITU..:

Wu, J. Q. ; Seymour, J. F. ; Eichhorst, B....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..